

Amendments to the Claims: This listing of claims will replace all prior versions, and listings of claims in the application

Listing of Claims:

1. (Currently Amended) A stent comprising:
 - a first section,
 - a second section and
 - at least one securement member, the at least one securement member disposed about at least one region of the first section and at least one region of the second section, the at least one securement member having an uncrimped diameter and a crimped diameter, the crimped diameter being less than the uncrimped diameter, when the at least one securement member is in the crimped diameter at least a portion of an inner surface of the at least one securement member is fixedly engaged to the at least one region of the first section and the at least one region of the second section, in the crimped diameter a seam at least partially separating the at least one region of the first section and the at least one region of the second section being immediately adjacent one another from each other, wherein at least a portion of the at least one region of the first section and at least a portion of the at least one region of the second section comprise at least one weld positioned along the seam.
2. (Original) The stent of claim 1 wherein at least one of the first section and second section is at least partially constructed of at least one wire.
3. (Original) The stent of claim 1 wherein at least one of the first section and second section is at least partially constructed of a plurality of struts, wherein adjacent struts define at least one cell opening.
- 4.-5. (Cancelled)
6. (Currently Amended) The stent of claim [[4]] 1 wherein at least a portion of the at least one region of the first section and at least a portion of the at least one region of the second section are fused together along the seam.
7. (Currently Amended) The stent of claim 5-1 wherein the at least a portion of the at least one region of the first section and the at least a portion of the at least one region of the second

section and the at least a portion of the inner surface of the at least one securement member comprise the at least one weld.

8. (Currently Amended) The stent of claim 1 ~~further comprising at least one weld, wherein~~ the at least one weld is positioned between the at least a portion of the inner surface of the at least one securement member and at least one portion of at least one of the at least one region of the first section and the at least one region of the second section.

9. (Currently Amended) The stent of claim 8 wherein the at least one weld is selected from ~~at least one member of the group consisting of:~~ at least one seam weld, at least one spot weld and any combination thereof.

10. (Currently Amended) A stent comprising:
a first section;
a second section;
at least one securement member, the at least one securement member disposed about
at least one region of the first section and at least one region of the second section, the at least
one securement member having an uncrimped diameter and a crimped diameter, the crimped
diameter being less than the uncrimped diameter, when the at least one securement member is
in the crimped diameter at least a portion of an inner surface of the at least one securement
member is fixedly engaged to the at least one region of the first section and the at least one
region of the second section, in the crimped diameter the at least one region of the first section
and the at least one region of the second section being immediately adjacent one another;
at least one weld positioned between the at least a portion of the inner surface of the at
least one securement member and at least one portion of at least one of the at least one region
of the first section and the at least one region of the second section; and
The stent of claim 8 further comprising at least one strengthening member, at least a portion of
the at least one strengthening member positioned between ~~against~~ the at least a portion of an
inner surface of the at least one securement member and the at least one portion of at least
one of the at least one region of the first section and the at least one region of the second
section.

11. (Original) The stent of claim 10 wherein the at least one weld is positioned between the at least a portion of the inner surface of the at least one securement member, the at least one

portion of at least one of the at least one region of the first section and the at least one region of the second section, and the at least a portion of the at least one strengthening member.

12. (Original) The stent of claim 1 further comprising at least one strengthening member, the at least one strengthening member comprising a first portion and a second portion, the first portion of the at least one strengthening member positioned between the at least a portion of an inner surface of the at least one securement member and at least one portion of at least one of the at least one region of the first section and the at least one region of the second section, the second portion extending beyond an end of the at least one securement member.

13. (Original) The stent of claim 12 wherein at least one of the first portion and the second portion of the at least one strengthening member has a length of about 2 mm.

14. (Original) The stent of claim 12 wherein the at least one strengthening member is at least partially constructed of at least one metal selected from the group consisting of nitinol, stainless steel, platinum, gold and any combination thereof.

15. (Original) The stent of claim 12 wherein the at least one strengthening member is at least partially radiopaque.

16. (Original) The stent of claim 12 wherein the at least one strengthening member has a thickness, the thickness being about 0.01 inches to about 0.02 inches.

17. (Original) The stent of claim 12 wherein the at least one strengthening member has a thickness, the thickness being about 0.015 inches.

18. (Currently Amended) The stent of claim 1 wherein at least one of the first section and second section is characterized by being from the group consisting of self-expandable, balloon expandable, and hybrid expandable and any combination thereof.

19. (Original) The stent of claim 1 wherein the first section is a balloon expandable stent body and the second section is a self-expandable stent body.

20. (Original) The stent of claim 1 wherein at least one of the first section and second section is at least partially constructed of a shape memory material.
21. (Original) The stent of claim 1 wherein at least one of the first section and second section is at least partially constructed of nitinol.
22. (Original) The stent of claim 1 wherein the at least one securement member is at least partially constructed of the group consisting of: stainless steel, nickel, titanium, gold, platinum, and any combinations thereof.
23. (Original) The stent of claim 1 wherein the at least one securement member is at least partially constructed of nitinol.
24. (Original) The stent of claim 1 wherein the at least one securement member is at least partially radiopaque.
25. (Original) The stent of claim 1 wherein the at least one securement member has a thickness the thickness being about 0.001 inches to about 0.01 inches.
26. (Original) The stent of claim 1 wherein the at least one securement member has a thickness the thickness being about 0.003 to about 0.007 inches.
27. (Original) The stent of claim 1 further comprising a third section, the at least one securement member disposed about the at least one region of the first section, the at least one region of the second section, and at least one region of the third section, when the at least one securement member is in the crimped diameter the at least a portion of the inner surface of the at least one securement member is fixedly engaged to the at least one region of the first section, the at least one region of the second section and the at least one region of the third section.
28. (Original) The stent of claim 1 wherein at least a portion of the stent is coated with at least one therapeutic agent.

Amendment Dated December 5, 2006
Reply to Office Action of September 12, 2006

29. (Original) The stent of claim 28 wherein the at least a portion of the stent is at least a portion of the at least one securement member.

30. (Currently Amended) The stent of claim 28 wherein the at least one therapeutic agent is at least one ~~non-genetic~~ therapeutic agent selected from ~~at least one member of the group consisting of:~~ ~~anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); anti-proliferative agents such as enoxaparin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine; antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; anesthetic agents such as lidocaine, bupivacaine and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg-chloromethyl keton, an RGD peptide containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; vascular cell growth promoters such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters; vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin; bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms, and any combinations thereof.~~

31. (Currently Amended) The stent of claim 28 wherein the at least one therapeutic agent is at least one ~~genetic~~ therapeutic agent selected from ~~at least one member of the group consisting of:~~ ~~anti-sense DNA and RNA; DNA coding for anti-sense RNA, tRNA or rRNA to replace defective or deficient endogenous molecules; angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor .alpha. and .beta., platelet derived endothelial growth factor, platelet derived growth factor, tumor necrosis factor .alpha., hepatocyte growth factor and insulin like growth factor; cell cycle inhibitors including CD~~

Amendment Dated December 5, 2006

Reply to Office Action of September 12, 2006

~~inhibitors, thymidine kinase ("TK") and other agents useful for interfering with cell proliferation; at least one of the family of bone morphogenic proteins ("BMP's") such as BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7; dimeric proteins such as homodimers, heterodimers, or combinations thereof, alone or together with other molecules; molecules capable of inducing an upstream or downstream effect of a BMP such as "hedgehog" proteins, or the DNA's encoding them; and any combinations thereof.~~

32. (Currently Amended) The stent of claim 28 wherein the at least one therapeutic agent is at least one type of cellular material selected from at least one member of the group consisting of: cells of human origin (autologous or allogeneic); cells of non-human origin (xenogeneic); and any combination thereof.

33. (Currently Amended) The stent of claim 28 wherein the at least one therapeutic agent comprises at least one polymer coating, the at least one coating selected from at least one member of the group consisting of: polycarboxylic acids; cellulosic polymers, including cellulose acetate and cellulose nitrate; gelatin; polyvinylpyrrolidone; cross-linked polyvinylpyrrolidone; polyanhydrides including maleic anhydride polymers; polyamides; polyvinyl alcohols; copolymers of vinyl monomers such as EVA; polyvinyl ethers; polyvinyl aromatics; polyethylene oxides; glycosaminoglycans; polysaccharides; polyesters including polyethylene terephthalate; polyacrylamides; polyethers; polyether sulfone; polycarbonate; polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene; halogenated polyalkylenes including polytetrafluoroethylene; polyurethanes; polyorthoesters; proteins; polypeptides; silicones; siloxane polymers; polylactic acid; polyglycolic acid; polycaprolactone; polyhydroxybutyrate valerate and blends and copolymers thereof; coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL.RTM., etc.), fibrin, collagen and derivatives thereof; polysaccharides such as celluloses, starches, dextrans, alginates and derivatives; hyaluronic acid; squalene emulsions; polyacrylic acid, a copolymer of polylactic acid and polycaprolactone; medical-grade biodegradable materials such as PGA-TMC, Tyrosine-Derived Polycarbonates and arylates; polycaprolactone co butyl acrylate and other copolymers; Poly-L-lactic acid blends with DL-Lactic Acid; Poly(lactic acid-co-glycolic acid); polycaprolactone co PLA; polycaprolactone co butyl acrylate and other copolymers; Tyrosine-Derived Polycarbonates and arylate; poly amino acid; polyphosphazenes; polyiminocarbonates; polydimethyltrimethylcarbonates; biodegradable CA/PO.sub.4's; cyanoacrylate; 50/50 DLPLG;

polydioxanone; polypropylene fumarate; polydepsipeptides; macromolecules such as chitosan and Hydroxylpropylmethylcellulose; surface erodible material; maleic anhydride copolymers; zinc-calcium phosphate; amorphous polyanhydrides; sugar; carbohydrate; gelatin; biodegradable polymers; and polymers dissolvable in bodily fluids; and any combinations thereof.

34. (New) A stent comprising:
 - a first section;
 - a second section;
 - a securement member disposed about the first section and the second section, wherein an inner surface of the securement member is fixedly engaged to the first section and the second section, wherein the securement member comprises a seam at least partially separating the first section and the second section from each another; and
 - a weld positioned along the seam.
35. (New) The stent according to claim 34, comprising a plurality of securement members.
36. (New) The stent according to claim 34, comprising a plurality of welds.
37. (New) The stent of claim 30 wherein the anti-thrombogenic agents are selected from the group consisting of heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone).
38. (New) The stent of claim 30 wherein the anti-proliferative agents are selected from the group consisting of enoxaprin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid.
39. (New) The stent of claim 30 wherein the anti-inflammatory agents are selected from the group consisting of dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine.
40. (New) The stent of claim 30 wherein the antineoplastic/antiproliferative/anti-miotic agents are selected from the group consisting of paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors.

41. (New) The stent of claim 30 wherein the anesthetic agents are selected from the group consisting of lidocaine, bupivacaine and ropivacaine.
42. (New) The stent of claim 30 wherein the anti-coagulants are selected from the group consisting of D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides.
43. (New) The stent of claim 30 wherein the vascular cell growth promoters are selected from the group consisting of growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters.
44. (New) The stent of claim 30 wherein the vascular cell growth inhibitors are selected from the group consisting of growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, and bifunctional molecules consisting of a growth factor and a cytotoxin.
45. (New) The stent of claim 31 wherein the growth factors are selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factors, epidermal growth factors, transforming growth factors .alpha. and .beta., platelet-derived endothelial growth factors, platelet-derived growth factors, tumor necrosis factors .alpha., hepatocyte growth factors, and insulin like growth factors.
46. (New) The stent of claim 31 wherein the cell cycle inhibitors are selected from the group consisting of CD inhibitors, thymidine kinase ("TK") and other agents useful for interfering with cell proliferation.
47. (New) The stent of claim 31 wherein the bone morphogenic proteins are selected from the group consisting of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16.

48. (New) The stent of claim 31 wherein the molecules capable of inducing an upstream or downstream effect of a BMP are selected from the group consisting of "hedgehog" proteins, and the DNA's encoding "hedgehog" proteins.
49. (New) The stent of claim 33 wherein the coatings from polymer dispersions are selected from the group consisting of polyurethane dispersions, fibrin, collagen and derivatives thereof.
50. (New) The stent of claim 33 wherein the polysaccharides are selected from the group consisting of celluloses, starches, dextrans, alginates and derivatives.
51. (New) The stent of claim 33 wherein the medical-grade biodegradable materials are selected from the group consisting of PGA-TMC, Tyrosine-Derived Polycarbonates and arylates.
52. (New) The stent of claim 33 wherein the macromolecules are selected from the group consisting of chitosan and Hydroxylpropylmethylcellulose.